title: Flow cytometric evaluation of red blood cell chimerism after bone marrow transplantation in Iranian patients: a preliminary study.
abstract: The aim of this study was to evaluate mixed red cells population and red blood cell chimerism after hematopoietic stem cell transplantation. Red blood cell chimerism after hematopoietic stem cell transplantation was analyzed using a series of fluorescein isothiocyanate-conjugated monoclonal antibodies (BioAtlantic, France) directed against ABH, Rh (D, C, E, c, e), Kell, Duffy, Kidd, and Ss antigens on blood samples of 14 patients with hematologic disorders undergoing hematopoietic stem cell transplantation, by flow cytometric method on days 15, 30, and 60 after transplantation. All patients showed expression of donor red cell antigens within days 15 - 30 after hematopoietic stem cell transplantation. Graft versus host disease and ABO incompatibility did not affect the expression of chimerism. Flow cytometric analysis is a simple, accurate, and valuable test which is of significant help in monitoring chimerism in allogeneic hematopoietic stem cell transplantation.
authors.affiliation: Department of Immunology, Iranian Blood Transfusion Organization Research Center (IBTORC), Tehran, Iran. shaiegan@ibto.ir
authors.forename: Mojgan
authors.initials: M
authors.lastname: Shaiegan
authors.forename: Esmerdis
authors.initials: E
authors.lastname: Hadjati
authors.forename: Mahnaz
authors.initials: M
authors.lastname: Aghaiipour
authors.forename: Masoud
authors.initials: M
authors.lastname: Iravani
authors.forename: Gaelle
authors.initials: G
authors.lastname: David
authors.forename: Daniel
authors.initials: D
authors.lastname: Bernard
mesh_terms: D000017:ABO Blood-Group System; D000293:Adolescent; D000328:Adult; D000911:Antibodies, Monoclonal / Q000737:chemistry; D000970:Antineoplastic Agents / Q000494:pharmacology; D016026:Bone Marrow Transplantation / Q000379:methods*; D002648:Child; D004912:Erythrocytes / Q000166:cytology*; D005260:Female; D005434:Flow Cytometry / Q000379:methods*; D016650:Fluorescein-5-isothiocyanate / Q000494:pharmacology; D006086:Graft vs Host Disease / Q000628:therapy; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007492:Iran; D008297:Male; D014740:Vidarabine / Q000031:analogs & derivatives / Q000494:pharmacology
chemical_list: D000017:ABO Blood-Group System; D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D014740:Vidarabine; D016650:Fluorescein-5-isothiocyanate; C024352:fludarabine